GlobalData on MSN2d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trialDaiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
3don MSN
Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant ...
Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...
Daiichi Sankyo announces establishment of upper limits for acquisition of own shares: Tokyo, Japan Saturday, March 1, 2025, 10:00 Hrs [IST] Daiichi Sankyo Company, Limited (hereaf ...
Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...
Terumo Vietnam and Daiichi Sankyo Vietnam Co., Ltd. signed an MoU on February 26 to enhance cardiology expertise across ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback